دورية أكاديمية
أعرض في EDS

Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4

التفاصيل البيبلوغرافية
العنوان: Efficacy and safety of a novel, nebulized glycopyrrolate for the treatment of COPD: effect of baseline disease severity and age; pooled analysis of GOLDEN 3 and GOLDEN 4
المؤلفون: Ohar J, Tosiello R, Goodin T, Sanjar S
المصدر: International Journal of COPD, Vol Volume 14, Pp 27-37 (2018)
بيانات النشر: Dove Medical Press, 2018.
سنة النشر: 2018
المجموعة: LCC:Diseases of the respiratory system
مصطلحات موضوعية: Age, COPD, disease severity, LAMA, nebulized glycopyrrolate, Diseases of the respiratory system, RC705-779
الوصف: Jill Ohar,1 Robert Tosiello,2 Thomas Goodin,2 Shahin Sanjar2 1Department of Internal Medicine, Wake Forest University School of Medicine, Winston-Salem, NC, USA; 2Sunovion Pharmaceuticals Inc., Marlborough, MA, USA Background: The efficacy and safety of nebulized glycopyrrolate inhalation solution (GLY), administered twice daily (BID) via the innovative eFlow® Closed System nebulizer (PARI Pharma GmbH, Starnberg, Germany), were demonstrated in two replicate, placebo-controlled, 12-week Phase III studies (GOLDEN 3 and GOLDEN 4). This report evaluates the efficacy and safety of GLY by baseline disease severity and age in the pooled GOLDEN 3 and GOLDEN 4 patient population (N=1,294). Methods: Patients were grouped by baseline predicted post-bronchodilator FEV1 (
نوع الوثيقة: article
وصف الملف: electronic resource
اللغة: English
تدمد: 1178-2005
Relation: https://www.dovepress.com/efficacy-and-safety-of-a-novel-nebulized-glycopyrrolate-for-the-treatm-peer-reviewed-article-COPD; https://doaj.org/toc/1178-2005
URL الوصول: https://doaj.org/article/e06d993eed024c769f24cc95de89a753
رقم الأكسشن: edsdoj.06d993eed024c769f24cc95de89a753
قاعدة البيانات: Directory of Open Access Journals
الوصف
تدمد:11782005